SPRY Stock Analysis: Buy, Sell, or Hold?
SPRY - ARS Pharmaceuticals, Inc. Common Stock
$5.51
0.00 (0.00%)
â˛
5d:
-2.57%
30d:
-8.25%
90d:
-33.11%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When SPRY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: SPRY is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: SPRY is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: SPRY is currently trading at $5.50, which is considered slightly low relative to its 30-day fair value range of $5.43 to $6.81.
Technical Outlook: Technically, SPRY is in a downtrend. Immediate support is located at $5.00, while resistance sits at $6.58.
Market Sentiment: SPRY scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $23.25 (+272.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SPRY is in a downtrend. Immediate support is located at $5.00, while resistance sits at $6.58.
Market Sentiment: SPRY scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $23.25 (+272.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$5.43 -
$6.81
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 272.6% below Wall St target ($23.25)
- WARNING: Composite score 46/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.43 -
$6.81
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$5.00
Resistance Level
$6.58
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.01
Wall Street Target
$23.25
(+272.6%)
Revenue Growth (YoY)
114.2%
Profit Margin
-184.2%
Share & Embed Analysis
Last updated: August 23, 2026 11:49 PM ET
Data refreshes hourly during market hours. Next update: 12:49 AM
Data refreshes hourly during market hours. Next update: 12:49 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SPRY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 41 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
|
RNA
Atrium Therapeutics, IncâĻ |
STRONG BUY
15 analysts |
$25 | 37 SELL |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 50 HOLD |
